Plain-English translation of NCT06243393 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called sacituzumab govitecan in patients with metastatic colorectal cancer—cancer that has spread to other parts of the body and no longer responds to standard chemotherapy. The study will first treat 20 patients with this medication to see if it is safe and effective. If promising results are seen, the trial will then compare this medication to other standard treatment options in 60 additional patients to find out which approach works best.
Colorectal cancer that has spread and become resistant to standard chemotherapy treatments is very difficult to manage, and patients urgently need new options. This medication works differently than traditional chemotherapy, and researchers believe it may help patients whose cancer has stopped responding to earlier treatments.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new medication as an infusion into your vein. The study has two parts: first, 20 patients will receive the medication to test its safety and effectiveness; if results look promising, 60 more patients will be enrolled and randomly assigned to either receive the medication or continue with standard treatment that your doctor recommends. Throughout the study, you will have regular visits to receive treatment, have blood tests, and undergo imaging scans to monitor how the cancer is responding. Patients receiving standard treatment can switch to the new medication if their cancer worsens.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany